Melanoma Clinical Trials in Arizona

Showing 161-180 of 271 trials

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Head and Neck CancerMelanomaHPV-Related Malignancy+5 more

Repertoire Immune Medicines22 participantsStarted May 2021

Scottsdale, Arizona, United States • Ann Arbor, Michigan, United States • Nashville, Tennessee, United States

COMPLETEDPhase 131 miles

A Study of PLX2853 in Advanced Malignancies.

NCT03297424

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more

Opna Bio LLC49 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Miami, Florida, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 131 miles

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic Melanoma+1 more

Bristol-Myers Squibb395 participantsStarted Oct 2008

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +10 more locations

PreviousPage 9 of 14Next

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

A Study of PLX2853 in Advanced Malignancies.

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Melanoma Trials in Other Cities

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Safety Study of MGA271 in Refractory Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Other Conditions in Arizona